BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhang Y, Huang ZX, Song B. Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma. World J Gastroenterol 2021; 27(22): 3037-3049 [PMID: 34168406 DOI: 10.3748/wjg.v27.i22.3037]
URL: https://www.wjgnet.com/1007-9327/full/v27/i22/3037.htm
Number Citing Articles
1
Kai Wang, John D. Karalis, Ahmed Elamir, Alessandro Bifolco, Megan Wachsmann, Giovanni Capretti, Paola Spaggiari, Sebastian Enrico, Kishore Balasubramanian, Nafeesah Fatimah, Giada Pontecorvi, Martina Nebbia, Adam Yopp, Ravi Kaza, Ivan Pedrosa, Herbert Zeh, Patricio Polanco, Alessandro Zerbi, Jing Wang, Todd Aguilera, Matteo Ligorio. Delta Radiomic Features Predict Resection Margin Status and Overall Survival in Neoadjuvant-Treated Pancreatic Cancer PatientsAnnals of Surgical Oncology 2024; 31(4): 2608 doi: 10.1245/s10434-023-14805-5
2
Victor Hugo Fonseca de Jesus, Rachel P. Riechelmann. Current Treatment of Potentially Resectable Pancreatic Ductal Adenocarcinoma: A Medical Oncologist’s PerspectiveCancer Control 2023; 30 doi: 10.1177/10732748231173212
3
Madeline T. Olson, Eric N. Aguilar, Cory L. Brooks, Carly C. Isder, Kathryn M. Muilenburg, Geoffrey A. Talmon, Quan P. Ly, Mark A. Carlson, Michael A. Hollingsworth, Aaron M. Mohs. Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic CancerMolecular Pharmaceutics 2022; 19(10): 3586 doi: 10.1021/acs.molpharmaceut.2c00203
4
Tomoyuki Kawada. Prognostic factors in patients with pancreatic ductal adenocarcinoma with neoadjuvant treatment and pancreatectomyJournal of Surgical Oncology 2022; 125(6): 1071 doi: 10.1002/jso.26819
5
Luis Secanella, Juli Busquets, Núria Peláez, María Sorribas, Berta Laquente, Sandra Ruiz, Thiago Carnaval, Sebastián Videla, Juan Fabregat. Predictive factors for resection and survival in type A borderline resectable pancreatic ductal adenocarcinoma patients after neoadjuvant therapy: A retrospective cohort studyMedicine 2022; 101(48): e32126 doi: 10.1097/MD.0000000000032126
6
Thais Gazzi, Marina Lesina, Qinghua Wang, Alexandra Berninger, Silke Radetzki, Ihsan Ekin Demir, Larissa Kohlmann, Waldemar Meiser, Sebastian Wilke, Jens Peter von Kries, Hana Algül, Hai‐Yu Hu, Marc Nazare. DOTA‐Based Plectin‐1 Targeted Contrast Agent Enables Detection of Pancreatic Cancer in Human TissueAngewandte Chemie International Edition 2024;  doi: 10.1002/anie.202318485
7
Chao Qu, Piao‐e Zeng, Hang‐yan Wang, Chun‐hui Yuan, Hui‐shu Yuan, Dian‐rong Xiu. Application of Magnetic Resonance Imaging in Neoadjuvant Treatment of Pancreatic Ductal AdenocarcinomaJournal of Magnetic Resonance Imaging 2022; 55(6): 1625 doi: 10.1002/jmri.28096
8
Thais Gazzi, Marina Lesina, Qinghua Wang, Alexandra Berninger, Silke Radetzki, Ihsan Ekin Demir, Larissa Kohlmann, Waldemar Meiser, Sebastian Wilke, Jens Peter von Kries, Hana Algül, Hai‐Yu Hu, Marc Nazare. DOTA‐Based Plectin‐1 Targeted Contrast Agent Enables Detection of Pancreatic Cancer in Human TissueAngewandte Chemie 2024;  doi: 10.1002/ange.202318485
9
Yun Bian, Hui Jiang, Jianming Zheng, Chengwei Shao, Jianping Lu. Basic pancreatic lesions: Radiologic-pathologic correlationJournal of Translational Internal Medicine 2022; 10(1): 18 doi: 10.2478/jtim-2022-0003
10
Bo Zhou, Shi-Ran Zhang, Geng Chen, Ping Chen. Developments and challenges in neoadjuvant therapy for locally advanced pancreatic cancerWorld Journal of Gastroenterology 2023; 29(35): 5094-5103 doi: 10.3748/wjg.v29.i35.5094
11
Wenke Yin, Xiaoyan Song, Yue Xiang. WDR79 promotes aerobic glycolysis of pancreatic ductal adenocarcinoma (PDAC) by the suppression of SIRT4Open Medicine 2023; 18(1) doi: 10.1515/med-2022-0624
12
Amanda Puleo, Midhun Malla, Brian A. Boone. Defining the Optimal Duration of Neoadjuvant Therapy for Pancreatic Ductal AdenocarcinomaPancreas 2022; 51(9): 1083 doi: 10.1097/MPA.0000000000002147